Martina Lorenzi - Publications

Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 02, 2026

Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives.

Journal: Cancers

Published: January 12, 2025

Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment.

Journal: Journal for immunotherapy of cancer

Published: June 13, 2024

Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.

Journal: Journal of clinical medicine

Published: May 09, 2024

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

Journal: The oncologist

Published: October 17, 2023

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.

Journal: Frontiers in immunology

Published: October 05, 2023

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

Journal: Seminars in oncology

Published: May 03, 2023

Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.

Journal: The oncologist

Published: April 05, 2023

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World.

Journal: Frontiers in oncology

Published: March 31, 2022

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.

Journal: The oncologist

Published: September 05, 2021

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.

Journal: The oncologist

Published: June 24, 2021

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.

Journal: Future oncology (London, England)

Published: May 14, 2021